New drugs: Evidence relating to their therapeutic value after introduction to the market;Neue Arzneimittel: Verfügbarkeit von Daten zum therapeutischen Stellenwert bei Markteinführung

Deutsches Arzteblatt International

Volumn 109, Issue 7, 2012, Pages 117-123

  Ujeyl, Mariam ^a   Schlegel, Claudia ^a   Walter, Siegbert ^a   Gundert Remy, Ursula ^a  

^a Drug Commission of the German Medical Association   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; PROPRIETARY MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; EUROPEAN UNION; HUMAN; POPULATION; RETROSPECTIVE STUDY;

EID: 84903362462     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0117     Document Type: Article

References (25)

1. Europäische Arzneimittel-Agentur: Zulassung und Überwachung von Arzneimitteln-Europäische Arzneimittel-Agentur: http://europa.eu/ legislation-summaries/internal-market/single-market-for-goods/ pharmaceutical-and-cosmetic-products/l22149-de.htm#amendingact. last accessed on 1st June 2011.
2. EMA: Status of EMEA scientific guidelines and European pharmacopoeia monographs and chapters in the regulatory framework applicable to medicinal products; www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/10/WC500004008.pdf.EMEA/42371/2008; London, 11. September 2008-corr. last accessed on 1st June 2011.
3. EMA: European public assessment reports: www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/general/general-content-000433.jsp&murl=&mid=. last accessed on 1st June 2011.
4. Garattini S, Bertele V: The role of the EMEA in regulating pharmaceutical products. In: Mossialos E, Mrazek M, Walley T (eds.): Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Open University Press; Maidenhead: European Observatory on Health Systems and Policies Series 2004.
5. Hart D: Risk-benefit evaluation of medicinal products. An element of health technology assessment. Bundesgesundheitsbl-Gesundheitsforsch- Gesundheitsschutz 2005; 48: 204-14.
6. Hoag H: Cancer drugs should add months, not weeks, say experts. Nat Med 2011; 17: 7.
7. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (eds.): Allgemeine Methoden-Version 4.0; www.iqwiq.de/download/IQWIQ-Methoden-Version-4-0.pdf. Köln, 23.09.2011. last accessed on 1st october 2011.
8. Lasser KE, Allen PD, Woolhandler SJ, et al.: Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-20.
9. Waller PC, Tilson HH: Managing drug safety issues with marketed products. In: Talbot J, Waller P (eds.): Stephen's detection of new adverse drug reactions. 5th Edition. Chichester, West Sussex: John Wiley & Sons Ltd 2004; 345-74.
10. Hess R: Die Frühbewertung des Nutzens neu zugelassener Arzneimittel. GGW 2011; 11: 8-14.
11. Arzneimittelkommission der deutschen Ärzteschaft: Neue Arzneimittel: www.akdae.de/Arzneimitteltherapie/NA/index.html. last accessed on 23 September 2011.
12. Honig PK: Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther 2011; 89: 151-6.
13. Eudra Lex: EudraLex-Volume 1-Pharmaceutical legislation medicinal products for human use: http://ec.europa.eu/health/documents/eudralex/vol-1/ index-en.htm. last accessed on 1st June 2011.
14. van Luijn JC, Gribnau FW, Leufkens HG: Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 2007; 63: 159-62.
15. EMA: Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available: www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2011/01/WC500100710.pdf. EMA/759784/2010; London, November 2010. last accessed on 23 September 2011.
16. Sorenson C, Naci H, Cylus J, Mossialos E: Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ 2011; 343: d4849.
17. AIM, International Society of Drug Bulletins, Medicines in Europe Forum: EMA suggestions on comparative clinical trials fall back behind ethical and scientific standards: www.isdbweb.org/documents/uploads/press/Press-Release2011- 03-31.pdf. Brüssel, Bielefeld, Paris, 31. März 2011. last accessed on 23 September 2011.
18. Loke YK, Price D, Herxheimer A: Adverse effects. In: Higgins JPR, Green S (eds.): Cochrane handbook of systematic reviews. Chichester: Wiley-Blackwell 2008; 433-48.
19. Stephens M: Introduction. In: Talbot J, Waller P (eds.): New adverse drug reactions. 5th Edition. West Sussex, England: John Wiley & Sons Ltd 2004.
20. Lewis J: Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93-4.
21. EMA: Guideline on the evaluation of anticancer medicinal products in man. CPMP/EWP/205/95/Rev.3/Corr.2; London, 14. December 2005. last accessed on 1st June 2011.
22. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (eds.): Aussagekraft von Surrogatendpunkten in der Onkologie. Köln: IQWiG 2011.
23. Schwabe U, Paffrath D (eds.): Arzneiverordnungs-Report 2010. Heidelberg, Berlin: Springer Medizin Verlag 2010.
24. Drummond MF: The use of health economic information by reinbursement authorities. Rheumatology 2003; 42 (Suppl. 3): iii60-iii63.
25. Gemeinsamer Bundesausschuss (G-BA): Gemeinsamer Bundesausschuss beschließt erste Festbetragsgruppen unter Einbeziehung patentgeschützter Arzneimittel. www.g-ba/institution/presse/ pressemitteilungen/52./Berlin, 15. Juni 2004; last accessed on 1st June 2011.